Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

How to Reconstitute CJC-1295 without DAC

CJC-1295 without DAC is a GHRH analogue supplied as a lyophilised research peptide. This page covers its identifiers, the GH-IGF-1 axis work it is used to study, and the laboratory handling and reconstitution considerati

peptides-pro Editorial

CJC-1295 without DAC — also written as CJC-1295 no DAC, and referred to in the literature as a growth hormone-releasing hormone (GHRH) analogue — is a synthetic peptide supplied to laboratories as a lyophilised powder that must be brought into solution before use. The evidence block for this page does not provide a sequence, molecular formula, molecular weight, or CAS number for the compound, so none are stated here. In the peptide literature it is grouped with the GHRH analogues, alongside sermorelin, tesamorelin, and CJC-1295 with Drug Affinity Complex (DAC), and distinguished from the growth hormone secretagogues such as GHRP-2, GHRP-6, hexarelin, and ipamorelin [1].

The work around this compound centres on the growth hormone–insulin-like growth factor-1 (GH-IGF-1) axis, the endocrine pathway that GHRH analogues are used experimentally to modulate [1].

Research Studies

CJC-1295 without DAC and the GH-IGF-1 axis

Reviews of performance-enhancing peptides describe GHRH analogues, including CJC-1295 without DAC, as agents intended to modulate the GH-IGF-1 axis. These compounds are encountered both in clinical practice and in online self-administration protocols, and they are frequently marketed as "research compounds" despite sitting outside the regulated pharmaceutical supply chain [1]. The same review places CJC-1295 without DAC in a class that also contains sermorelin, tesamorelin, and CJC-1295 with DAC, and separates that class from the growth hormone secretagogues and from the GH fragment AOD9604 (hGH 176-191) [1].

CJC-1295 and HIV-associated visceral obesity

The clinical trial record for CJC-1295 is dominated by a Phase 2 study in a specific population: patients with human immunodeficiency virus (HIV) associated visceral obesity. That trial was multicentre, randomised, placebo-controlled, and double-blind, with participants assigned to low-dose CJC-1295, high-dose CJC-1295, or placebo. Treatment ran for 12 weeks, followed by a 6-week follow-up period, and the stated objective was to assess and compare efficacy, pharmacokinetics, safety, and tolerability in that population [6]. Note that this registration describes CJC-1295 without specifying the DAC variant, and that the population studied was HIV patients with visceral obesity — not healthy adults and not athletes.

CJC-1295 without DAC and the research-compound supply chain

An evaluation of research-grade peptides marketed directly to consumers examined purity, measured abundance, and endotoxin burden using a large publicly available independent testing dataset, and compared cost against compounded and FDA-approved alternatives. The study drew on 6,441 data points and framed the problem as a rapidly expanding drug class with a parallel, largely unregulated gray market selling preparations directly to consumers for self-administration [2]. For a laboratory, the relevant point is that the identity and purity of a supplied peptide cannot be assumed from the label alone.

CJC-1295 without DAC and the peptide therapeutics literature

A narrative review of therapeutic peptides in gerontology examined mechanisms, clinical applications, evidence base, and safety profiles for peptides with demonstrated or potential applications in healthy aging and age-related conditions. It identified metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline among the hallmarks of aging that peptide therapeutics are proposed to target, and drew on PubMed, Scopus, and regulatory databases including the FDA and WADA [3]. CJC-1295 without DAC is not the subject of that review; it sits within the broader class the review surveys.

CJC-1295 without DAC and musculoskeletal or performance claims

Reviews of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance describe peptides as short amino acid chains occupying a pharmacological niche between small-molecule drugs and large proteins. They note that use in sports medicine is expanding in response to patient demand for accelerated injury recovery and performance enhancement, and that a parallel gray market of unapproved compounds operates largely outside regulatory oversight [4][5]. The same framing appears in a structured narrative review of injectable peptides in sports medicine, which reports that clinical adoption has outpaced high-quality evidence and regulatory consensus, and which summarises human and translational evidence published between 1 January 2020 and a later cut-off [8]. A critical review of peptide and peptide-analogue use in recreational and professional sport and bodybuilding describes a shift from anabolic-androgenic steroids toward peptides marketed as more selective and ostensibly safer alternatives, naming growth hormone secretagogues such as ipamorelin among them [10]. A further review of peptide supplements in sports medicine reports that these products are often perceived as low risk despite the absence of efficacy and safety data [7].

CJC-1295 without DAC and the limits of the evidence base

Across these sources the recurring finding is a mismatch between marketing and data. Peptides are promoted for musculoskeletal recovery, tissue repair, and performance enhancement while high-quality evidence and regulatory consensus lag behind clinical adoption [8]. Products are sold directly to patients and athletes, are often perceived as low risk, and are frequently unapproved [4][7][9]. For CJC-1295 without DAC specifically, the evidence block for this page supplies no animal-only or in vitro study, and no human efficacy data in healthy populations. The only registered clinical study cited here concerns CJC-1295 in HIV patients with visceral obesity [6].

CJC-1295 without DAC and product variability

The independent testing dataset described above compared gray-market research peptides against compounded and FDA-approved alternatives on purity, measured abundance, endotoxin burden, and cost [2]. That comparison is the most directly relevant evidence for anyone handling a lyophilised research peptide in a laboratory, because it addresses the material itself rather than a proposed mechanism.

ParameterWhat the evidence block reports
Formal nameCJC-1295 without DAC (also written CJC-1295 no DAC) [1]
ClassGHRH analogue [1]
Related analoguesSermorelin, tesamorelin, CJC-1295 with DAC [1]
Distinct fromGHRP-2, GHRP-6, hexarelin, ipamorelin; AOD9604 (hGH 176-191); IGF-1 analogue [1]
PathwayGH-IGF-1 axis [1]
Sequence / formula / MWNot provided in the evidence block
Registered clinical study citedPhase 2, HIV patients with visceral obesity, 12 weeks treatment plus 6 weeks follow-up [6]

CJC-1295 without DAC and reconstitution practice

The evidence block does not contain a reconstitution protocol, diluent specification, concentration table, or storage instruction for CJC-1295 without DAC. What it does contain is a body of work establishing that research-grade peptides sold directly to consumers vary in purity, measured abundance, and endotoxin burden [2], and that the wider category is used in sport and bodybuilding outside regulatory oversight [10]. Those two findings are the ones a laboratory can act on: verify the material, and treat the category as one where the label is not the evidence.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp